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Abstract
Introduction. Plasmacytomas are malignant tumors char-
acterized by abnormal monoclonal proliferation of plasma
cells. They originate in either bone – solitary osseous  plas-
macytoma, or in soft tissue – extramedullary plasmacytoma
(EMP). EMP represents less than 1% of all head and neck
malignancies. Case report. We presented a case of EMP of
the nasal septum in a 44-year-old male who had progressive
difficulty in breathing through the nose and frequent heavy
epistaxis on the right side. Nasal endoscopy showed dark
red, soft, polypoid tumor in the last third of the right nasal
cavity arising from the nasal septum. The biopsy showed
that it was plasmacytoma. Bence Jones protein in the urine,
serum electrophoresis, bone marrow biopsy, skeletal survey
and other screening tests failed to detect multiple myeloma.
This confirmed the diagnosis of EMP. The mass was com-
pletely removed via an endoscopic approach, and then, 4
week later, radiotherapy was conducted with a radiation
dose of 50 Gray. No recurrence was noted in a 3-year fol-
low-up period. Conclusion. EMP of the nasal cavity, being
rare and having long natural history, represents a diagnostic
and therapeutic challenge for any ear, nose and throat sur-
geon. Depending on the resectability of the lesion, a com-
bined therapy is the accepted treatment.
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Apstrakt
Uvod. Plazmocitomi predstavljaju maligne tumore koji se ka-
rakterišu abnormalnom proliferacijom plazma ýelija poreklom
iz jednog klona. Nastaju ili u kostima – usamljeni koštani plaz-
mocitom, ili u mekim tkivima – ekstramedularni plazmocitom
(EMP). Manje od 1% svih malignih tumora glave i vrata ÿini
EMP. Prikaz bolesnika. U radu je prikazan muškarac star 44
godine sa EMP, koji se javio na pregled zbog progresivnog ote-
žanog disanja na nos i ÿestih epistaksi iz desne nosne šupljine.
Endoskopijom nosa uoÿen je tamnocrven, mek, polipoidni iz-
raštaj u zadnjoj treýini desne nosne šupljine, polazišta sa nosne
pregrade. Patohistološki (PH) nalaz ukazao je na plazmocitom.
U urinu nije bio Bence-Jonesovih proteina, elektroforeza seru-
ma, biopsija koštane srži, RTG nalazi skeleta i ostali skrining te-
stovi nisu pokazali da se radi o multiplom mijelomu, što je pot-
vrdilo dijagnozu EMP. Tumor je kompletno uklonjen endos-
kopskim pristupom, a 4 nedelje nakon operacije, sprovedena je
zraÿna terapija, radijacijskom dozom od 50 Gray-a. Tokom 3-
godišnjeg praýenja bolesnika nije ustanovljen recidiv tumora.
Zakljuÿak. Zbog svog rariteta i nespecifiÿnih simptoma, koji
mogu dugo da budu neprepoznati, EMP nosa predstavlja i di-
jagnostiÿki i terapijski izazov za svakog otorinolaringologa. U
odnosu na operabilnost tumora, kombinovan pristup (hirurgija
i radioterapija) predstavlja prihvatljiv tretman.
Kljuÿne reÿi:
plazmocitom; nos, septum; dijagnoza; dijagnoza,
diferencijalna; hirurgija, otorinolaringološka,
procedure; leÿenje, ishod.
Introduction
Plasmacytomas are malignant tumors characterized
by abnormal monoclonal proliferation of plasma cells.
They originate in either bone (solitary osseous plasmacy-
toma) or in soft tissue (extramedullary plasmacytoma –
EMP) 
1, and could be either primary (without evidence of
disease in other foci) or a part of a systemic process during
the course of multiple myeloma. The etiology of EMP is
unknown.
The first case of EMP was reported in 1905 by
Schridde. 
2 Alexiou et al. 
3 reviewed all previous reports of
EMP and found 869 cases; 714 (82.2%) of them had oc-
curred in the upper aerodigestive tract. The most frequently
affected areas in the upper aerodigestive tract were the nasal
cavity or paranasal sinuses (43.8%), followed by nasophar-Strana 222 VOJNOSANITETSKI PREGLED Volumen 70, Broj 2
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ynx (18.3%), oropharynx (17.8%), and larynx (11.1%) 
3.
Wax et al. 
4 report that 75% of extramedullary plasmacyto-
mas occur in the sinonasal/nasopharyngeal area, 12% in the
oropharynx, 8% in the larynx. Other sites in the head and
neck that have been reported include the tongue, minor sali-
vary glands, thyroid, parotid, orbit and temporal bone 
4. EMP
affects men 3–4 times more often in women and typically
occurs in the 6th to 7th decade, with over 95% of cases oc-
curring in patients above 40 years of age 
5. EMP is a de-
structive tumor and, beside the tendency for local recur-
rence 
5, 6, has the ability to spread to regional lymph nodes
and ability for distant metastasis with progression to multiple
myeloma. EMP is rare tumor and represents less than 1% of
all head and neck malignancies 
7, 8 and it accounts for 4% of
all nonepithelial tumors of the nasal cavity, nasopharynx, and
paranasal sinuses 
9.
The rarity of this tumor and its long natural history repre-
sent a diagnostic and therapeutic challenge for any ear, nose
and throat (ENT) surgeon. To exclude multiple myeloma or
plasmacytoma of the bone, a systemic work-up and follow-up
of the patient are mandatory, including serum protein electro-
phoresis, urin analysis for the Bence-Jones protein, skeletal
survey and bone marrow biopsy 
10, 11. The optimal manage-
ment of EMP is controversial. However, based on the well-
known radiation sensitivity of plasma-cell tumors, radiother-
apy is generally, accepted as the treatment of choice for EMP,
while the role of chemotherapy in these tumors is not well-
defined
 12. Surgery can achieve high rates of local control in
certain situations. However, radical excision is often impossi-
ble due to the size or the location of the tumor 
13.
Most reports in the literature, relating to EMP, are  de-
scriptions of individual cases. In this paper we described an
interesting case of EMP of nasal septum.
Case report
A 44-year-old male was admitted to the ENT Clinic,
Clinical Center in Kragujevac, due to progressive difficulty
in breathing through the nose at the right side in the last year
and frequent heavy epistaxis from the same side. Because of
that, in the past month, the patient was admitted to anterior
nasal packing three times. The patient was in good physical
condition, not consuming alcohol nor cigarettes, and not suf-
fering from any chronic disease.
Nasal endoscopy showed dark red, soft, polypoid tu-
mor, slightly bleeding to touch, in the right nasal cavity, ap-
proximately 2.5 cm in diameter, arising from the last third of
the nasal septum and provoking obstruction almost in the
entire nasal cavity, especially in its last third. The tumor ex-
tended toward the choana and obstructed it.
Computed tomography of the nasal cavities and parana-
sal sinuses with intravenous contrast showed a heterogenous
soft tissue mass, dimensions of approximately 3.5 u 2.0 u 1.5
cm, which arised from the last third of nasal septum, filling
the right nasal cavity with signs of mass effect of the medial
wall of the right maxillary sinus, locally thinned with no
signs of erosion. In the right maxillary sinus there was a
content of thicker consistency (Figure 1).
No cervical lymph nodes were palpable. Ultrasonogra-
phy of the neck and abdomen showed normal findings, and
lung X-ray did not show the presence of secondary deposits.
Fig. 1 – Computed tomography of paranasal sinuses (axial
view) shows a heterogenous soft tissue mass in the right
nasal cavity which arised from the last third of the nasal
septum and obstructing the choana
We performed biopsy of the tumor endoscopically. His-
topathologic findings, complemented by immunohistochemi-
cal examination, fully stressed the intermediate differentiation
(Gr. 2 – intermediate grade) extramedullary tumor originating
from plasma cells (tumor cells were clearly positive for
CD79Į, MUM-1, CD138, CD38 and lambda) (Figure 2).
Fig.  2 – Histological and immunohistochemical
characteristics of plasmacytomas
(original magnification, u 200)
a) HE staining techniques – the tumor is easily constructed from polymorphic
cells, high N/C ratio, large roundish nuclei, prominent nucleoli, basophilic
cytoplasm easy; immunohistochemically, the cells were plasmacvtomas: b)
lambda positive, c) intensively express CD79Į, d) MUM1, e) CD138  and  f)
CD38, while negative for: g) Ae1/Ae3  and  h) CD20.Volumen 70, Broj 2 VOJNOSANITETSKI PREGLED Strana 223
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After this histopathologic findings, a systemic work-up
to exclude (or confirm) multiple myeloma was performed.
Renal and liver function were normal. Measurements of he-
matocrit, white blood cells, blood urea, serum creatinine, se-
rum electrolytes, serum calcium, serum protein electrophore-
sis and immunoelectrophoresis were within normal limits.
Bone marrow biopsy and complete skeletal radiographic sur-
vey (skull, AP and profile of cervical, thoracic and lumbar
spine, chest, pelvis and long bones of extremities) were
negative. Bence Jones protein was absent in the urine.
Since the possibility of multiple myeloma was ex-
cluded, the diagnosis of solitary extramedullary plasmacy-
toma of the nasal septum, stage 1 according to Wiltshaw,
was established. Because of the size and location of the tu-
mor, we decided to combine therapeutic approach. The pa-
tient underwent complete surgical removal of the tumor via
transnasal endoscopy. Four week later, the patient received
radiotherapy with a radiation dose of 50 Gray in 25 fractions.
No recurrence was detected at clinical examination or at
CT scan performed during the first (Figure 3), second and
third year after the treatment.
Fig. 3 – Computed tomography of paranasal sinuses (axial
view) a year after the treatment, shows the normal anatomy
Discussion
It is important for otolaryngologists to recognize EMP
since 80% of EMP occur in the head and neck as single le-
sions and 10%–20% of cases may present with multiple le-
sions 
6. This tumor is characterized by a slow clinical course,
atypical symptoms, noncharacteristic clinical picture and un-
timely recognition. The diagnosis is somewhat difficult to
made because of nonspecific CT and MRI features of soli-
tary EMP of the sinonasal tract 
14. Although several reports
regarding EMP in the nasal cavity have been published so
far, a finding of such a lesion in the nasal septum is quite
rare. For all these reasons, initially we were not thinking of
EMP in the presented patient.
Physical examination usually reveals  submucosal, dark
red to grayish red, sessile or polypoid tumor, which bleeds
easily with manipulation. The mucosa is typically intact but
ulceration and necrosis may occur in advanced cases. Clini-
cal presentation is primarily a function of the mass effect and
varies according to the site of involvement. Because most of
these lesions arise in the sinonasal or nasopharyngeal area,
the most common symptoms are nasal mass, nasal obstruc-
tion, and epistaxis 
15. In Kapadia et al. 
5 series of 20 patients
of EMP of the head and neck, 80% of patients presented with
the complaint of a mass or swelling, 35% of patients com-
plained of airway obstruction, 35% complained of epistaxis,
20% of localized pain, 15% with proptosis, 10% with nasal
discharge, 10% with regional lymphadenopathy, and 5%
with a VI nerve palsy.
The diagnosis of EMP usually follows histologic ex-
amination. Immunohistochemical staining will demonstrate
the monoclonal nature of plasma cells and confirm the neo-
plastic nature of the lesion. In addition, immunohistochemi-
cal study, too, is used to differentiate EMP from other malig-
nant disorders, such as undifferentiated carcinoma, mela-
noma, and esthesioneuroblastoma 
15, 16. When plasmacytoma
is confirmed histologically, secondary diagnostic procedures
must be carried out to exclude systemic involvement. A sys-
temic work-up including complete blood profile, renal and
liver function, calcium, serum and urinary protein electro-
phoresis, serum immunoglobulin level, complete skeletal ra-
diographic survey and bone marrow biopsy.
After the diagnosis have been confirmed, EMP can be
staged as follows: stage 1 – limited to an extramedullary site
(localized and controllable disease), stage 2 – involvement of
regional lymph nodes or local extension, and stage 3 – mul-
tiple metastasis (although it is no longer a solitary plasma-
cytoma). In our case the finding confirmed the diagnosis of
stage 1 extramedullary plasmacytoma.
The treatment of localized EMP of the head and neck
somewhat is controversial. Some authors advocate radiation
therapy alone and others advocate surgery alone. Based on
the documented radiation sensitivity of plasma cell tumors,
the accepted treatment is radiotherapy, but radiotherapy does
not always reduce the size of the tumor, perhaps because of
an abundant deposition of amyloid within the mass 
17–19.
Therefore, most clinicians recommend a combined approach
(surgery and radiotherapy) for the management of nasal cav-
ity extramedullary plasmacytoma 
6, 19–22. In fact, a combina-
tion treatment may provide the best results. Alexiou et al. 
3 in
their review of 714 cases of upper aerodigestive tract extra-
medullary plasmacytomas reported between 1905–1997,
found that the median overall survival or recurrence free sur-
vival was longer than 300 months for patients who under-
went combined surgery and radiotherapy as compared to a
median survival rate of 144 months for patients who under-
went only radiotherapy and 156 months for only surgically
managed patients. Chemotherapy may be considered for pa-
tients with refractory or relapsed disease.
The median survival of patients varies from 4–10 years.
Local recurrence has been reported to occur in 8%–30% of
adequately treated EMP in the upper aerodigestive tract 
6, 23.
Because of the tendency of EMP to progress into dissemi-
nated multiple myeloma (conversion of EMP to multiple
myeloma has been reported in 8%–36% of cases within 3 to
61 months), 
24 a lifelong follow-up of these patients is rec-Strana 224 VOJNOSANITETSKI PREGLED Volumen 70, Broj 2
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ommended. CT and measurements of serum immunoglobulin
and urinary Bence Jones protein levels may be useful in de-
tecting recurrence or conversion to multiple myeloma 
25.
Conclusion
Extramedullary plasmacytoma of the nasal cavity is
rare and should be considered in the differential diagnosis
of nasal cavity masses. A multidisciplinary approach (hae-
matologist, otorhinolaryngologist, pathologist, radiation
oncologist, radiologist) is required for the optimal diagno-
sis and management of EMP. It is essential to exclude any
systemic involvement before arriving at a diagnosis of
solitary EMP. Depending on lesion resectability, a com-
bined therapy (surgery and radiotherapy) is the treatment of
choice.
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